Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir

, , ,

On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy and Infectious Diseases (NIAID) to test oral formulations of remdesivir in preclinical models. Remdesivir is owned by Gilead Sciences and the lipid nanocrystal platform is owned by Matinas.

Tags:

Source: Matinas BioPharma
Credit:

Visit News/History Source
LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.